切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2019, Vol. 13 ›› Issue (07) : 540 -543. doi: 10.3877/cma.j.issn.1674-0785.2019.07.012

所属专题: 文献

综述

结直肠癌肝转移局部治疗的研究进展
敬聪1, 任勇军1,(), 邓进1, 闵旭立1, 徐浩1, 陈智粮1   
  1. 1. 637000 四川南充,川北医学院附属医院介入放射科,四川省医学影像重点实验室
  • 收稿日期:2019-02-13 出版日期:2019-04-01
  • 通信作者: 任勇军
  • 基金资助:
    四川省教育厅自然类科研基金(17ZB0169); 南充市科技局自然类科研基金(16YFZJ0054)

Progress in local treatment of liver metastasis of colorectal cancer

Cong Jing1, Yongjun Ren1,(), Jin Deng1, Xuli Min1, Hao Xu1, Zhiliang Chen1   

  1. 1. Department of Interventional Radiology, Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China
  • Received:2019-02-13 Published:2019-04-01
  • Corresponding author: Yongjun Ren
  • About author:
    Corresponding author: Ren Yongjun, Email:
引用本文:

敬聪, 任勇军, 邓进, 闵旭立, 徐浩, 陈智粮. 结直肠癌肝转移局部治疗的研究进展[J/OL]. 中华临床医师杂志(电子版), 2019, 13(07): 540-543.

Cong Jing, Yongjun Ren, Jin Deng, Xuli Min, Hao Xu, Zhiliang Chen. Progress in local treatment of liver metastasis of colorectal cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(07): 540-543.

结直肠癌是常见的消化道恶性肿瘤,易发生肝转移。外科手术切除肝转移病灶是重要治疗方法之一。随着临床诊疗技术的进步,介入治疗、放射治疗等方法已成为结直肠癌肝转移的重要治疗手段。本文将对结直肠癌肝转移局部治疗的研究进展进行综述。

Colorectal cancer is a common gastrointestinal malignancy, which is prone to liver metastasis. Surgical resection of liver metastases is one of the important treatment methods. With the progress of clinical diagnosis and treatment technology, interventional therapy, radiotherapy, and other methods have become important options of treatment for colorectal cancer liver metastasis. This article will review the progress in local treatment of liver metastasis of colorectal cancer.

[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136: E359-E386.
[2]
Brenner H, Kloor M, Pox CP. Colorectal cancer [J]. Lancet, 2014, 383(9927): 1490-1502.
[3]
Levy J, Zuckerman J, Garfinkle R, et al. Hepatic intra-arterial therapies for unresectable and chemo-refractory colorectal cancer liver metastases: systematic review and pooled analysis [J]. HPB, 2017, 19(1): S53.
[4]
Tomlinson JS, Jarnagin WR, DeMatteo RP. Actual 10-year survival after resection of colorectal liver metastases defines cure [J]. J Clin Oncol, 2007, 25(29): 4575-4580.
[5]
House MG, Kemeny NE, Gönen M. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer [J]. Ann Surg, 2011, 254(6): 851-856.
[6]
Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from color ectal cancers: an update [J]. J Hepatobiliary Pancreat Surg, 2008, 15(6): 570-580.
[7]
Norén A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases, a nationwide study [J]. Eur J Cancer, 2016, 53: 105-114.
[8]
Norén A, Sandstrom P, Gunnarsdottir K, et al. Identification of inequalities in the selection of liver surgery for colorectal liver metastase in Sweden [J]. Scand J Surg, 2018, 4(107): 294-301.
[9]
Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status [J]. World J Radiol, 2010, 2(11): 417-424.
[10]
Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013 [J]. Eur Radiol, 2015, 25(12): 3438-3454.
[11]
Cheng JQ, Weng M, Zhang Y, et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a metaanalysis [J]. PLoS One, 2012, 7(9): e45493.
[12]
Babawale SN, Jensen TM, Frkjr JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: a retrospective study [J]. World J Gastrointest Surg, 2015, 7(3): 33-38.
[13]
Sucandy I, Cheek S, Golas BJ, et al. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors [J]. HPB( Oxford), 2016, 18(9): 756-763.
[14]
Lee BC, Lee HG, Park IJ, et al. The role of radiofrequency ablation for treatment of metachronous isolated hepatic metastasis from colorectal cancer [J]. Medicine (Baltimore), 2016, 95( 39): e4999.
[15]
Zarour LR, Anand S, Billingsley KG, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions [J]. Cell Mol Gastroenterol Hepatol, 2017, 3(2): 163-173.
[16]
Stang A, Oldhafer KJ, Weilert H, et al. Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal [J]. BMC Cancer, 2014, 14: 500.
[17]
Tombesi P, Di VF, Sartori S. Resection vs thermal ablation of small hepatocellular carcinoma: what′s the first choice? [J]. World J Radiol, 2013, 5(1): 1-4.
[18]
Shono Y, Tabuse K, Tsuji T, et al. Microwave coagulation therapy for unresectable colorectal metastatic liver tumor [J]. Gan To Kagaku Ryoho, 2002, 29(6): 856-859.
[19]
Grundmann RT, Hermanek P, Merkel S, et al. Diagnosis and treatmen t of colorectal liver metastases workflow [J]. Zentralbl Chir, 2008, 133(3): 267-284.
[20]
Correa-Gallego C, Fong Y, Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases [J]. Ann Surg Oncol, 2014, 21(13): 4278-4283.
[21]
Song KD. Percutaneous cryoablation for hepatocellular carcinoma [J]. Clin Mol Hepatol, 2016, 22(4): 509-515..
[22]
Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma [J]. Hepatology, 2015, 61(5): 1579-1590.
[23]
Rong G, Bai W, Dong Z, et al. Longterm outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria [J]. PloS One, 2015, 10(4): e0123065.
[24]
Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population [J]. Cardiovasc Intervent Radiol, 2014, 37(1): 154-164.
[25]
Breedis C, Young G. The blood supply of neoplasms in the liver [J]. Am J Pathol, 1954, 30(5): 969-977.
[26]
含笑. 肝转移癌TACE疗效评价及影响因素分析[D].合肥:安徽医科大学, 2013.
[27]
Li C, Gu Y, Zhao M, et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer [J]. Cancer Chemother Pharmacol, 2014, 74(5): 1079-1087.
[28]
Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer [J]. J Cancer Res Clin Oncol, 2015, 141(3): 543-553.
[29]
Hoyer M, Roed H, Traberg Hansen A, et al. PhaseⅡ study on stereotactic body radiotherapy of colorectal metastases [J]. Acta Oncol, 2006, 45(7): 823-830.
[30]
van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases [J]. Br J Surg, 2010, 97(3): 377-382.
[31]
Ren ZG, Zhao JD, Gu K, et al.Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study [J]. Int J Radiat Oncol Biol Phys, 2011, 79(2): 496-502.
[32]
van Hazel GA, Heinemann V, Sharma NK, et al.SIRFLOX: randomized phase Ⅲ trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2016, 34(15): 1723-1731.
[33]
周定中, 曹苏娟, 李庆, 等. TACE联合DC-CIK生物治疗结直肠癌肝转移的临床应用 [J].临床放射学杂志, 2016, 35(5): 771-774.
[34]
翟霏霏. 树突状细胞疫苗联合射频消融术治疗结直肠癌转移临床疗效[D].合肥: 安徽医科大学, 2016.
[35]
吴倩, 张文涛, 沈健美. 高能聚焦超声刀联合化疗治疗不能手术的结直肠癌肝转移的近期疗效 [J]. 现代肿瘤医学, 2016, 24(17): 2755-2758.
[1] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[2] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[3] 谢田伟, 庞于樊, 吴丽. 超声引导下不同消融术对甲状腺良性结节体积缩减率、复发率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 80-83.
[4] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[5] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[6] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[7] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[8] 何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
[9] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[10] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[11] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[14] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[15] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?